NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality. 52 Week Range 2.38 - 48.80. in 2020 the stock was $77. My price target is 16.50 If this is not the time to buy this stock, then when?!
NRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant. Information was released by Israel Institute for Biological Research. Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines. I consider this a premium call, the upside i see here is 400%, or the 24usd...
After a perfect touch of the .618 Fib retracement level, now NRXP is ready to aim higher! Get ready for action! My first price target is 35usd. Today NRx was granted Fast Track Designation by the U.S. Food and Drug Administration for ZYESAMI (aviptadil) for the treatment of Critical COVID-19 with respiratory failure! NRx Pharmaceuticals has also a Partnership...